S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC）

Prior treatment

• Female in pregnancy or lactation, or refuse to receive Contraception measures during chemotherapy.
• Unavailable for R0 resection and D2 lymph node dissection.
• Patients (within 4 weeks) are receiving any other anti-cancer drugs therapy, biological therapy, radiation therapy, or Immunosuppressive therapy.

Other illness

• Suffering from other uncontrolled diseases, such as other tumors, acute and Chronic infection.
• With severe heart disease, including congestive heart failure, uncontrolled arrhythmias, unstable angina, myocardial infarction, severe heart valve disease, and resistant hypertension.
• Any Known or suspected history of drug allergy test.
• Patients conform to any of the following: post-organ transplant, necessary for long-term immunosuppressive or suffering with autoimmune diseases.

Other

• Patients with stage I, III and IV.
• The researchers believe the patient is not able to complete the entire course of the experiment.

• The lower age limit of research subjects 18 years old and upper age limit of 75 years old.
• Be proven to be primary adenocarcinoma of gastric cancer and staged II by pathological evidence
• R0 surgery with lymphadenectomy
• Without any other malignancies
• ECOG (ECOG score standard) performance status of 0 or 1 and expected to survive more than 6 months
• No contraindications to chemotherapy, including normal peripheral blood routine, liver, and kidney function and electrocardiogram （WBC≥4.0 x 109 /L, NEU≥1.5 x 109 /L, PLT≥100 x 109 /L and HGB≥90g/L).